The Ministry of Food and Drug Safety has included 'medical institutions and pharmacies handling growth hormone drugs' and 'cold chain compliance of high-risk items such as vaccines' in this year's planned inspections.

The ' Biopharmaceuticals and Herbal Medicine Bureau’s Basic Plan for Manufacturing and Distribution Management in 2024,' which was released by the MFDS on the 15th, contains this year's planned joint surveillance for biopharmaceutical manufacturers and importers, drug advertisers, and wholesalers.

The planned joint surveillance program is designed to preemptively respond to hazardous factors that threaten public safety, including growth hormone drugs, which became a